MedTrace Logo

Hypofractionated Stereotactic Boost in Prostate Cancer

NCT01596816 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 76

Last updated 2026-03-13

No results posted yet for this study

Summary

hypofractionated stereotactic boost radiation (prostate) after normofractionated radiotherapy (prostate + seminal vesicles).

Conditions

Interventions

RADIATION

First part of treatment : Conformal irradiation

23 fractions (2 Gy/session), are delivered over 42 days maximum, for a total dose of 46 Gy

PROCEDURE

Fiducials placement

Placement of intra-prostatic markers for the tracking

RADIATION

Second part : hypofractionated stereotactic boost

3 fractions (6Gy/session) are delivered over 5 to 9 days (at least 48 hours between sessions) for a total dose of 18 Gy

Sponsors & Collaborators

  • National Cancer Institute, France

    collaborator OTHER_GOV

  • Centre Oscar Lambret

    lead OTHER

Principal Investigators

  • Eric LARTIGAU, MD, PhD · Centre Oscar Lambret

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-08-31
Primary Completion
2016-09-30
Completion
2018-09-01

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01596816 on ClinicalTrials.gov